Live Remote Cardiac MRI Exam to Showcase Vista.ai’s Automated and Virtual Scan Capabilities at ACC.23/WCC

Vista.ai, a pioneer and leader in automated MRI solutions, today announced that Dr. Michael Salerno, Chief, Cardiovascular Imaging at Stanford Health Care, will conduct a live remote cardiac MRI (CMR) scan using the company’s One Click MRI™ software at the American College of Cardiology’s 72nd Annual Scientific Session Together With World Heart Federation’s World Congress of Cardiology (ACC.23/WCC). Dr. Salerno will scan a patient at Stanford Health in Palo Alto, Calif., virtually from the ACC.23/WCC Future Hub stage in New Orleans at 11 a.m. CST on March 5, 2023

Dr. Salerno will be joined by Dr. Raymond Kwong, Director, Cardiac Magnetic Resonance Imaging for Harvard-affiliated Brigham and Women’s Hospital, who will present updated results from an ongoing clinical adaptation study that shows One Click MRI significantly reduces CMR scan times and improves image consistency. A case study summarizing Dr. Kwong’s previously released clinical findings, including data from the first six months and 1,100 patients, is available at vista.ai/evidence/studies. This case study will also be on display and discussed at Vista.ai’s ACC booth (#FH22) in the Future Hub. 

CMRs are considered the gold-standard cardiac diagnostic; however today, specially-trained CMR technologists need to perform an exam, and in the U.S., there is only one such technologist for every 20 MRI machines. One Click MRI’s benefits include simple, streamlined workflows and improved image consistency, so any MRI technologist can complete a cardiac scan in a regular mixed-use MRI time slot. 

The supply-demand imbalance for CMRs has only worsened since the onset of COVID-19, which has driven a rise in heart attacks and led to a 14% increase in heart attack deaths. Among the hardest hit are adults, aged 25-44, who had a 29.9% relative rise in heart attack deaths over the first two years of the pandemic. Furthermore, Penn State College of Medicine conducted a study, which found that people who contracted COVID-19 were 15 times more likely to develop myocarditis, an inflammation of the heart muscle. With patient wait times for CMR lengthening across the U.S., the need for faster scanner throughput is dire.

“The recent surge in cardiac conditions attributed to COVID-19 has led to an unprecedented demand for CMR, including in younger patients. The scarcity of qualified technologists and the increased demand is limiting access to CMR. To do more with less, we need to turn to AI and automation,” Dr. Salerno said. “With Vista.ai’s One Click MRI, CMRs are much more efficient and streamlined, which greatly improves our ability to scan patients who need them. This is especially critical as we continue to study the full impact that COVID has on the heart.” 

In addition to simplifying clinical workflows and shortening scan times, One Click MRI allows technologists, wherever they are available, to conduct a patient scan at a remote hospital, so long as the facility has an MRI scanner. This serves to expand the geographic reach of CMR  and ensures that patients in isolated, rural areas of the country, where the shortage of MRI technicians is even more pronounced, can still receive an exam.

“CMRs should not be limited to people who live in close proximity to the largest and best resourced hospitals,” said Itamar Kandel, Vista.ai’s CEO. “Until now, smaller regional and community hospitals have struggled to get a CMR program off the ground due to scheduling challenges on mixed-use scanners, lack of trained staff, and quality inconsistencies. CMR’s differentiators are well-established, and it’s Vista.ai’s mission to ensure access to anyone who can benefit.”

While One Click MRI is initially focused on automating and simplifying a CMR exam, Vista.ai recently announced planned expansion beyond the heart to other anatomies and clinical areas.

SourceVista.Ai

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”